COVID-19 drug trial pulled before it started
NCT ID NCT04605926
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to test whether the drug itolizumab could help hospitalized COVID-19 patients recover faster. The trial was planned for 18 years and older with confirmed COVID-19 pneumonia and low oxygen levels. However, the study was withdrawn before enrolling any participants, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONAVIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Inv Site CO01
Medellín, Colombia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental drug aims to tame severe COVID-19 inflammation
- Scientists create COVID-19 biobank to unlock disease secrets
- Placenta cells tested as COVID fighter – but trial stopped early
- Plasma from COVID-19 survivors tested as treatment for the critically ill
- Study tracks virus shedding in COVID-19 contacts
- Could a simple breath test replace nasal swabs for COVID-19?